LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

2.29 0.44

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.27

Max

2.38

Chiffres clés
By Trading Economics
Revenu	2.6M -39M
Employés	150
EBITDA	-1.4M -39M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+282.02% upside

Dividendes
By Dow Jones
Prochains Résultats	13 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	225M 787M
Ouverture précédente	1.85
Clôture précédente	2.29

Sentiment de l'Actualité

By Acuity

34%

66%

94 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.18 / 1.69 Support & Résistance

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2026, 22:50 UTC

Résultats

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mai 2026, 22:49 UTC

Résultats

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mai 2026, 22:32 UTC

Résultats

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mai 2026, 22:57 UTC

Market Talk

Résultats

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mai 2026, 22:26 UTC

Résultats

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mai 2026, 22:24 UTC

Résultats

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mai 2026, 22:19 UTC

Résultats

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mai 2026, 22:13 UTC

Résultats

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mai 2026, 22:11 UTC

Résultats

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mai 2026, 22:11 UTC

Résultats

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mai 2026, 22:10 UTC

Résultats

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mai 2026, 22:08 UTC

Résultats

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mai 2026, 22:07 UTC

Résultats

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mai 2026, 22:05 UTC

Résultats

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

282.02% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 282.02%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

94 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.